Major Areas of Research
- Cryptococcosis in previously normal patients
- Idiopathic CD4 lymphocytopenia
- Clinical trials of antifungal agents
The Clinical Mycology Section focuses on pathogenesis, diagnosis, treatment, prevention, and epidemiology of mycoses, particularly cryptococcosis and candidiasis.
The incidence of cryptococcosis has risen dramatically in the United States since the onset of the HIV-1 epidemic. Most centers now report that 95 percent of their patients with cryptococcosis are co-infected with HIV-1. Peter Williamson, M.D., Ph.D., and Dr. Bennett are studying previously healthy patients with cryptococcal meningitis to discover underlying predisposing factors and improve therapy. Despite the absence of immunosuppression, these patients are surprisingly difficult to treat compared to those with AIDS and cryptococcosis. A major cause of morbidity and death is cerebral edema and increased intracranial pressure, which usually coexist. Our goals in studying these patients are as follows:
- Understanding the mechanisms causing cerebral edema and increased intracranial pressure
- Searching for genetic markers in the patients and their families that might have predisposed patients to cryptococcosis
- Assessing the role of corticosteroids in controlling cerebral edema
- Evaluating potential new treatments for cryptococcosis
Dr. Bennett received his B.S. in chemistry (cum laude) from Stanford University. He earned his M.D. (Alpha Omega Alpha) from The Johns Hopkins University School of Medicine. Dr. Bennett is board-certified in internal medicine and infectious disease. His other honors include master in the American College of Physicians; former president of the Infectious Diseases Society of America; charter president of the Greater Washington Infectious Diseases Society; member of the American Society for Clinical Investigation and the American Association of Physicians; co-editor of seven editions of Principles and Practice of Infectious Diseases; and consultant to the Centers for Disease Control and Prevention, American College of Physicians-American Society of Internal Medicine, U.S. Public Health Association, Food and Drug Administration, and U.S. Department of Defense.
Fukuda Y, Tsai HF, Myers TG, Bennett JE. Transcriptional profiling of Candida glabrata during phagocytosis by neutrophils and in the infected mouse spleen. Infect Immun. 2013 Apr;81(4):1325-33.
Noble JA, Tsai HF, Suffis SD, Su Q, Myers TG, Bennett JE. STB5 is a negative regulator of azole resistance in Candida glabrata.Antimicrob Agents Chemother. 2013 Feb;57(2):959-67.
Li QQ, Skinner J, Bennett JE. Evaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment. BMC Mol Biol. 2012 Jun 29;13:22.
Tsai HF, Sammons LR, Zhang X, Suffris SD, Su Q, Myers TG, Marr KA, Bennett JE. Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates. Antimicrob Agents Chemother. 2010 Aug;54(8):3308-17.
Bennett JE. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008. J Antimicrob Chemother. 2009 May;63 Suppl 1:i23-6.
Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008 Jul 1;47(1):e7-e10.